Navigation Links
China Interventional Cardiovascular Device Industry Report, 2013-2015
Date:11/20/2013

NEW YORK, Nov. 20, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

China Interventional Cardiovascular Device Industry Report, 2013-2015

http://www.reportlinker.com/p0370585/China-Interventional-Cardiovascular-Device-Industry-Report-2013-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People's Republic of China, in 2012 cardiovascular disease deaths in China reached 3.5 million. The fast growing number of heart patients stimulated rapid growth in Chinese demand for interventional cardiac operation and coronary stent. China's PCI (percutaneous coronary intervention) surgeries increased from 25,000 cases in 2002 to about 531,000 cases in 2012; the number of coronary stent implantation rose from 40,000 units in 2002 to approximately 640,000 units in 2012. In 2007-2012 China's cardiovascular stent market size grew at an AAGR of 20.3%.

In China, interventional cardiovascular devices are dominated by cardiovascular stent. Currently, the top three companies in China's coronary stent market are respectively MicroPort, Lepu Medical and JW Medical; while supporting auxiliary devices such as catheter and guide wire feature low localization rate, mainly dependent on imports. In 2012, Chinese enterprises accounted for 66.8% of Chinese interventional cardiovascular device market share, followed by foreign counterparts with 33.2%.

Interventional cardiovascular device is a sunrise industry, there lies strong clinical demand for safer and more effective interventional products, and thus the world's major manufacturers have invested heavily in research and development of new products. Bioabsorbable everolimus-eluting stent (BVS) has become the focus of attention. Abbott in September 2012 launched the world's first A bioabsorbable everolimus-eluting coronary stent system (ABSORB), expected to bring a revolutionary change in coronary artery disease (CAD) treatment; MicroPort's third-generation completely biodegradable drug-eluting stent Firehawk has completed clinical trials in China; Lepu Medical's completely biodegradable drug-eluting stent is also in active research and development.

China Interventional Cardiovascular Device Industry Report, 2013-2015 mainly covers the followings: Development, market demand, competition pattern, profit level, etc. of the industry;

Policy environment, impacts from upstream and downstream sectors, etc.;

Market size, supply and demand, product price, etc. of industry segments (including coronary stent, balloon catheter, guide wire, sheath group and auxiliary device), etc.;

Operation, interventional device cardiovascular business, operation in China, etc. of global companies (including Johnson & Johnson, Medtronic, Boston Scientific, Abbott Laboratories, B. Braun);

Operation, interventional cardiovascular device business, etc. of Chinese companies (including MicroPort, Lepu Medical, Lifetech Scientific, JW Medical, Liaoning Bio-medical Technology, OrbusNeich, SCW Medicath, Amtech Biotech and Starway Medical).

1. Overview of Interventional Cardiovascular Device Industry

1.1 Definition

1.2 Product Types and Applications

1.3 Industry Chain

2. Status Quo of China Interventional Cardiovascular Device Industry

2.1 Overview 2.2 Market Demand 2.3 Import and Export2.4 Competition Pattern2.5 Profit2.6 Entry Barriers2.6.1 Technology 2.6.2 Talent 2.6.3 Patent 2.6.4 Policy 2.6.5 Market Access

3. Development Environment for China Interventional Cardiovascular Device Industry

3.1 Policy Environment

3.1.1 Regulatory Policy

3.1.2 Industry Policy

3.2 Upstream and Downstream Sectors

3.2.1 Upstream

3.2.2 Downstream

4. Market Segments

4.1 Coronary Stent4.1.1 Market Profile4.1.2 Drug-Eluting Stent4.1.3 Bare Metal Stent4.1.4 Bioabsorbable Stent4.2 Balloon Catheter4.2.1 Market Profile4.2.2 Supply and Demand4.3 Catheter4.3.1 Market Profile4.3.2 Sales4.4 Guide Wire4.4.1 Market Profile4.4.2 Sales4.5 Sheath Group and Auxiliary Devices4.5.1 Market Profile4.5.2 Sales

5. Foreign Companies

5.1 Johnson & Johnson

5.1.1 Profile

5.1.2 Operation

5.1.3 Interventional Cardiovascular Device Business

5.1.4 Operation in China

5.2 Medtronic

5.2.1 Profile

5.2.2 Operation

5.2.3 Revenue Structure

5.2.4 Operation in China

5.3 Boston Scientific

5.3.1 Profile

5.3.2 Operation

5.3.3 Operation in China

5.4 Abbott Laboratories

5.4.1 Profile

5.4.2 Operation

5.4.3 Operation in China

5.5 B. Braun

5.5.1 Profile

5.5.2 Operation

5.5.3 Operation in China

6. Chinese Companies

6.1 MicroPort6.1.1 Profile6.1.2 Operation6.1.3 Revenue Structure6.1.4 Gross Margin6.1.5 R&D and Investment6.1.6 Interventional Cardiovascular Device Business6.1.7 Forecast and Outlook6.2 Lepu Medical6.2.1 Profile6.2.2 Operation6.2.3 Revenue Structure6.2.4 Gross Margin6.2.5 R&D and Investment6.2.6 Interventional Cardiovascular Device Business6.2.7 Forecast and Outlook6.3 Lifetech Scientific6.3.1 Profile6.3.2 Operation6.3.3 Revenue Structure6.3.4 Gross Margin6.3.5 R&D and Investment6.3.6 Interventional Cardiovascular Device Business6.4 JW Medical6.4.1 Profile6.4.2 Operation6.4.3 Development6.5 Liaoning Bio-medical6.5.1 Profile6.5.2 Operation6.5.3 Development6.6 OrbusNeich6.6.1 Profile6.6.2 Operation6.6.3 Development6.7 Sinomed6.7.1 Profile6.7.2 Operation6.7.3 Development6.8 SCW Medicath6.8.1 Profile6.8.2 Operation6.9 Amtech Biotech6.9.1 Profile6.9.2 Operation 6.10 Starway Medical

Companies Mentioned

Johnson & JohnsonMedtronicBoston ScientificAbbott LaboratoriesB. BraunMicroPortLepu MedicalLifetech ScientificJW MedicalLiaoning Bio-medicalOrbusNeichSinomedSCW MedicathAmtech BiotechStarway MedicalTo order this report: China Interventional Cardiovascular Device Industry Report, 2013-2015 http://www.reportlinker.com/p0370585/China-Interventional-Cardiovascular-Device-Industry-Report-2013-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices

_________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
2. CentraState and Freehold Radiology Group train physicians from China
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. ResearchMoz: Global and China 4A Zeolite Industry 2012 Deep Research Report - Market Research Report
5. China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY)
6. China Biologic Products Reports Higher Results for the First Quarter 2012
7. China Pharma Holdings, Inc. Reports First Quarter 2012 Financial Results
8. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
9. China Botanic Attends 67th PHARMCHINA Fair
10. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
11. China Botanic Attends the 111th China Import and Export Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... Technique, Repair Procedure By Technique, By Region, By Country (2016-2021)" ... ... at a CAGR of 13.35% during 2016-2021 The strong ... growth in population with heart disease and rising advances in minimally ...
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli ... the William Sansum Diabetes Center have established a research ... by diabetes through enhanced research, education and care. ... disease bears a disproportionate weight on Latino families in ... David Kerr , M.D., FRCPE, director of Innovation and ...
(Date:3/23/2017)... -- Summary Global Markets ... Primary Hyperoxaluria - Pipeline Review, H1 2017, provides ... System And Sex Hormones) pipeline landscape. Primary ... kidney and bladder stones. It results from the ... blood in the urine, pain when urinating, fever, ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF ... the greater Houston Area. The new location is located at 2255 E. Mossy Oaks ... Springwoods Village. This newest location will provide patients living in the north Houston area ...
(Date:3/23/2017)... ... , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the ... clinic is the group’s second in New Braunfels and 22nd in Texas. , TexPTS ... location brings things full circle for the group, “It’s crazy to think that we ...
(Date:3/23/2017)... ... , ... The IoT (Internet of Things) is revolutionizing the way the world ... businesses and individual consumers alike. Laboratories can maximize their profit margin by increasing ... $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT ...
(Date:3/23/2017)... ... 23, 2017 , ... 82% of adults are unaware of the dangers that infectious bacteria play ... the minimum two times a day that dentists recommend. The ramifications of improper oral upkeep ... school and adults missing 164 million hours of work each year due to dental issues. ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and thank ... Every day, two kidneys filter about 120 to 150 quarts of blood. Put another ... regulating fluid levels and blood pressure, supporting bone health and promoting red blood cell ...
Breaking Medicine News(10 mins):